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Abstract:  The  new  secondary  metabolites  verrucosidinol  (1)  and  its  derivative 
verrucosidinol acetate (2), together with a potent neurotoxin verrucosidin (3), a congener 
norverrucosidin (4) and a mixture of two known phytotoxic metabolites terrestric acids  
(5  and  6),  were  isolated  from  the  marine  derived  fungus  Penicillium  aurantiogriseum. 
Verrucosidinol has a ring-opened ethylene oxide moiety in the polyene -pyrone skeleton, 
and  verrucosidinol  acetate  is  its  acetate  derivative.  The  chemical  structures  were 
determined  by  comparing  with  literature  data  and  a  combination  of  spectroscopic 
techniques, including high resolution mass spectrum and two-dimentional nuclear magnetic 
resonance spectroscopic analysis. 
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1. Introduction 
Compared with the terrestrial environment, the marine habitat has some unique characteristics, such 
as high-pressure, high-salt, oxygen deficiency, and low nutrition. To survive in this harsh environment, 
oceanic life forms have evolved specific physiological and biochemical pathways to produce secondary 
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metabolites [1,2]. These chemicals may help them to guard against predators, prevent the adhesion of 
marine algae, and play an important  part in  the complicated signal transduction between different 
species. Among them, marine microorganisms in particular have the wide range of adaptability, leading 
to  the  distinctive  ability  to  produce  unprecedented  compounds  which  have  novel  structures  and 
significant bioactivity [3]. Natural products discovery from marine microbes has enjoyed a renaissance 
in recent years [4]. Many lead compounds have been obtained from marine microorganisms, such as 
salinosporamide A, azamerone, mechercharmycins A, and marinomycin A, thereby demonstrating that 
the marine environment, with its diverse microflora, is a very promising resource [4]. In our search for 
bioactive compounds from the marine environment, a marine microbial extract library was constructed 
and screened for various biological activities. The antifungal potentiator beauvericin has already been 
identified from this particular library, demonstrating that potentially more bioactive compounds could 
be found and some of the bioactive metabolites could be genetically engineered to further improve the 
yields [5–9]. 
Figure  1.  Six  (1–6)  compounds  isolated  from  the  extract  of  a  fungus  Penicillium 
verrucosum. 
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Penicillium  is  an  important  genus  in  toxigenic  fungi.  Chemical  investigation  of  Penicillium 
verrucosum  has  afforded  an  immunotoxin  ochratoxin  A,  which  threatens  human  health  through 
contaminated  food  in  a  wide  region  [10].  An  outbreak  of  neurological  disease  in  cattle  has  been 
reported in the USA [11]. The mycotoxin verrucosidin, from another variety Penicillium verrucosum 
var. cyclopium, was subsequently found to be responsible for the outbreak [12]. Verrucosidin is a 
down-regulator  of  UPR  (unfolded  protein  response)  induced  genes,  such  as  grp78,  resulting  in 
selective cell death under strict hypoglycemic conditions [13]. Furthermore, the nephrotoxic product Mar. Drugs 2010, 8                            
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from  an  adjacent  species  Penicillium  aurantiogriseum  is  a  possible  factor  in  Balkan  endemic 
nephropathy which has been confirmed in rats and hamsters [14,15]. During the chemical study of this 
genus,  some  cytotoxic  quinazoline  alkaloids,  and  an  antitumor  compound,  anicequol,  have  been 
identified  [16,17].  The  chemical  diversity  of  this  genus  and  the  peculiarity  of  the marine biotope 
prompted us to investigate the extract from a strain of Penicillium aurantiogriseum. With the aid of 
HPLC-diode  array  analysis,  two  new  verrucosidin  analogs,  named  verrucosidinol  (1)  and 
verrucosidinol acetate (2), together with norverrucosidin (3) and verrucosidin (4) were isolated from 
this marine-derived fungus (Figure 1). During the extraction and isolation procedure, a mixture of the 
phytotoxic metabolites terrestric acids (5 and 6) was also obtained [18]. Herein, we report the isolation, 
structure elucidation, and bioactivities of these compounds.  
2. Results and Discussion 
Compound 1 was obtained as yellow oil. The HRESIMS, in combination with 
1H and 
13C NMR 
data, indicated a composition of C24H34O7, requiring 8 unsaturations. The NMR spectra of 1 were 
compared to that of verrucosidin and found to be almost the same except for H-6/C-6, H-7/C-7, C-8 
and  C-10  [19–22].  Taking  into  account  the  degree  of  unsaturation,  the  molecule  should  have  a  
ring-opened structure. The 
1H and 
13C NMR spectra of compound 1 exhibited signals for 32 protons 
and 24 distinct carbons, respectively. A heteronuclear multiple-quantum coherency (HMQC) NMR 
experiment established all one-bond 
1H-
13C connections as indicated in Table 1. The heteronuclear 
multiplebond correlation (HMBC) NMR spectrum displayed 
1H-
13C couplings from the methyl protons 
18-H (δH 1.40) to C-5 (δC 159.7), C-6 (δC 78.8) and C-7 (δC 79.8), from the methyl protons 19-H  
(δH 1.82) to C-7 (δC 79.8), C-8 (δC 133.9) and C-9 (δC 134.3), and from the methyl protons 20-H  
(δH 1.89) to C-9 (δC 134.3), C-10 (δC 134.4), and C-11 (δC 133.0), thereby establishing the existence of 
a heptadiene moiety. The 
1H-
1H COSY NMR experiment revealed correlations from 9-H to 19-H, 9-H 
to 20-H and 20-H to 11-H supporting this conclusion. The 
13C NMR chemical shifts of five downfield 
signals  corresponding to  C-1 (δC 165.0), C-2 (δC 110.4), C-3 (δC 169.2), C-4 (δC 111.8) and C-5  
(δC 159.7), were in close agreement to those for an -pyrone unit [19,22,23]. Two singlet olefinic 
methyl protons 16-H (δH 2.01) and 17-H (δH 2.21) exhibited HMBC correlations to their adjacent 
carbons in the -pyrone moiety, C-1 (δC 165.0), C-2 (δC 110.4) and C-3 (δC 169.2); C-3 (δC 169.2), C-4 
(δC 111.8), and C-5 (δC 159.7), respectively, as indicated in Table 1. Additionally, the methoxy protons 
24-H  (δH  3.79)  revealed 
1H-
13C  coupling  to  a  quaternary  carbon  C-3  (δC  169.2),  indicating  the 
connection of the methoxy moiety to the C-3 position in the -pyrone substructure. The long range 
couplings from olefinic methyl protons 17-H (δH 2.21) to C-5 (δC 159.7), from the methyl protons  
18-H (δH 1.40) to C-5, and from the methine proton 7-H (δH 4.61) to C-5, indicated a connection 
between the partial heptadiene structure and the -pyrone moiety. The quartet methine protons 15-H 
(δH  4.12),  the  doublet  methyl  protons  23-H(δH  1.18),  and  the 
1H-
1H  COSY  signal  between  them 
suggested the methyl group was located at C-15. The long range couplings from the methyl protons  
22-H (δH 1.47) to C-14 (δC 67.4) and C-15 (δC 76.7), and from the doublet methyl protons 23-H  
(δH 1.18) to C-14 (δC 67.4) and C-15 (δC 76.7), linked the quaternary carbon C-14 to C-15. 
1H-
13C long 
range couplings from the methyl protons 21-H (δH 1.41) to C-11 (δC 133.0), C-12 (δC 80.1) and C-13 
(δC 67.5), from an oxygenated methine proton 13-H (δH 3.43) to C-12 (δC 80.1), and from an olefinic Mar. Drugs 2010, 8                            
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methine  proton  11-H  (δH  5.53)  to  C-12  (δC  80.1)  connected  the  quaternary  carbon  C-12  to  the 
heptadiene moiety. The two oxygenated carbons C-13 (δC 67.5) and C-14 (δC 67.4) were concluded to 
form an epoxide ring. In contrast, two further deshielded oxygenated carbons C-6 (δC 78.8) and C-7  
(δC 79.8), which had the higher chemical shifts, were connected to hydroxy groups respectively. This 
speculation was confirmed by the HRESIMS data. The molecular formula of 1 was determined from 
HRESIMS  as  C24H34O7,  corresponding  to  the  difference  of  one  water  molecule  in  the  molecular 
formula between 1 and 4. Therefore, compound 1 was suggested to be a ring-opened derivative of 4. 
On the basis of identical chemical shift values and coupling constants for both compounds, the 
relative configuration of the tetrahydrofuran in 1 was proposed to be the same as that of verrucosidin, 
which was assigned by X-ray crystal diffraction [24]. Key NOESY enhancements between 11-H and 
13-H, 13-H and 22-H, 23-H and 11-H, 22-H and 23-H, as well as a weak enhancement between 15-H 
and 21-H supported the orientations of these groups in tetrahydrofuran ring (Figure 3). The geometry of 
C-8  was  confirmed  to  be  E  by  the  NOE  observation  between  7-H  and  9-H.  And  the  NOESY 
enhancements  between  7-H  and  17-H,  18-H  and  19-H,  determined  their  steric  configuration 
respectively. 
Compound 2 possessed a molecular formula of C26H36O8 as determined by HRESIMS and NMR 
data. An additional C2H2O was the only difference compared with 1. Considering the similarity of the 
NMR data (Table 1), compound 2 was most probably an acetate derivative of 1. The characteristic 
NMR signals, quaternary carbon C-26 (δC 169.4), primary carbon C-25 (δC 21.0) and singlet methyl 
protons  25-H  (δH  2.06),  confirmed  this.  The  acetate  group  was  unambiguously  attached  to  C-7  
(δC 82.1), which was concluded from the correlation between H-7 (δH 5.43) and C-26 in the HMBC, 
shown in Figure 2. Further analysis of the HSQC, 
1H-
1H COSY and HMBC NMR data of 2 enabled 
the establishment of its structure. The NOESY NMR data of 2 was well matched to that of 1, except 
for an additional enhancement between 17-H and 25-H, which determined the relative configuration of 
the acetate ester group in position 7 (Figure 3). 
Compound 4 was obtained as colorless plates and established as verrucosidin by comparison of the 
spectroscopic data reported in the literature [12,19,24]. Verrucosidin is a potent neurotoxin which can 
cause  tremble  and paralysis experimentally in  mice [11,12]. It  was  first  isolated from  Penicillium 
verrucosum var. cyclopium, and then often found from the contaminated dry-cured ham [25]. Recently, 
the genotoxicity and chaperone down-regulate activity of verrucosidin has been reported [13]. 
Compound 3 was isolated as yellow oil. When its mass spectrum was compared with 4, the lack of 
one methyl group was concluded. By comparison with the reported data for normethylverrucosidin, its 
structure  was  assigned [12].  Normethylverrucosidin, together with  verrucosidin and terrestric acid, 
plays an important role in chemotaxonomy of terverticillate penicillia [26]. 
A mixture of compound 5 and 6 was obtained as colorless needles and determined as a mixture of 
terrestric acids. Since the corresponding peaks for both the cis- and trans-isomers were observed in the 
NMR data, it was established that this was a mixture of both cis- and trans-terrestric acids [18,27]. 
Terrestric acid was first isolated from Penicillium terrestre [28], and then from Pyricularia oryzae [18], 
and it has been reported to display phytotoxic activity.  
Although acetic acid was used during the isolation, none of derivatives of normethylverrucosidin 
were detected, which suggested that compounds 1 and 2 should be generated by the fungus instead of Mar. Drugs 2010, 8                            
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being artificial ring-opened product of 4. Considering the structural relationship between 1 and 2, the 
possibility still existed that compound 2 is the acetate esterified product brought about as an artifact 
process of 1. 
The compounds were also tested for bioactivity against methicillin resistant Staphylococcus aureus, 
Pseudomonas  aeruginosa,  Candida  albicans  SC5314,  and  synergistic  antifungal  activity  with 
ketoconazole.  Since  all  minimum  inhibitory  concentrations  (MICs)  of  tested  compounds  were  
≥64 μg/mL, no significant activity against the above-mentioned microbes was concluded. 
Table  1.  NMR  (500  MHz,  CDCl3)  Spectroscopic  Data  of  verrucosidinol  (1)  and 
verrucosidinol acetate (2). 
verrucosidinol (1)    verrucosidinol acetate (2) 
Position  δC  δH
a (J in Hz)  HMBC
a  NOESY    δC  δH
a (J in Hz)  HMBC
a  NOESY 
1  165.0, qC          164.3, qC       
2  110.4, qC          110.9, qC       
3  169.2, qC          168.5, qC       
4  111.8, qC          111.5, qC       
5  159.7, qC          157.5, qC       
6  78.8, qC          78.2, qC       
7  79.8, CH  4.61, s  5, 6, 8, 9, 18, 19  9, 17    82.1, CH  5.43, s  6, 8, 9, 19, 26  9, 17 
8  133.9, qC          130.4, qC       
9  134.3, CH  5.87, s  7, 11, 19, 20  7    135.4, CH  5.85, s  7, 11, 19, 20  7 
10  134.4, qC          134.3, qC       
11  133.0, CH  5.43, s  9, 12, 13, 20, 21,  13, 23    133.2, CH  5.41, s  9, 12, 13, 20  13, 23 
12  80.1, qC          80.0, qC       
13  67.5, CH  3.43, s  12  11, 22    67.4, CH  3.41, s  12  11, 22 
14  67.4, qC          67.4, qC       
15  76.7, CH  4.12, q (7.0)  12, 13  21    76.7, CH  4.11, q (7.0)  12, 13  21 
16  10.2, CH3  2.01, s  1, 2, 3      10.2, CH3  2.02, s  1, 2, 3   
17  9.9, CH3  2.21, s  3, 4, 5  7    10.1, CH3  2.20, s  3, 4, 5  7, 25 
18  23.4, CH3  1.40, s  5, 6, 7  19    23.8, CH3  1.55, s  5, 6, 7  19 
19  14.8, CH3  1.82, s  7, 8, 9,  18    15.4, CH3  1.80, s  7, 8, 9  18 
20  18.6, CH3  1.89, s  9,10,11      18.4, CH3  1.87, s  9, 10, 11   
21  21.9, CH3  1.41, s  11, 12, 13  15    21.8, CH3  1.39, s  11, 12, 13  15 
22  13.8, CH3  1.47, s  13, 14, 15  13, 23    13.8, CH3  1.46, s  13, 14, 15  13, 23 
23  18.8, CH3  1.18, d (7.0)  14, 15  11, 22    18.8, CH3  1.16, d (7.0)  14, 15  11, 22 
24  60.3, CH3  3.79, s  3      60.3, CH3  3.78, s  3   
25            21.0, CH3  2.06, s  26  17 
26            169.4, qC       
a HMBC NMR correlations (optimized for 8 Hz) are from proton(s) stated to the indicated carbon. 
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Figure 2. HMBC and 
1H-
1H COSY analysis of 2. 
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Figure 3. NOESY NMR analysis of 2. 
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3. Experimental Section 
3.1. General Experimental Procedures 
Optical rotations were measured on a Perkin-Elmer 241 MC polarimeter. IR spectra were recorded 
on  a  Nicolet  5700  FT-IR  microscope  spectrophotometer  (FT-IR  Microscope  Transmission).  NMR 
spectra were recorded on a Varian Inova 500 MHz spectrophotometer at 500.103 MHz for 
1H and 
125.762 MHz for 
13C in CDCl3 using solvent signals (CHCl3; δH 7.26/δC 77.10) as references; the 
coupling  constants  are  in  Hz.  ESIMS  data  were  recorded  on  a  Bruker  Esquire  3000plus 
spectrophotometer,  and  HRESIMS  data  were  obtained  using  Bruker  APEX  III  7.0T  and  APEXII  
FT-ICR  spectrophotometers,  respectively.  Column  chromatography  was  performed  with  silica  gel 
(200–300 mesh, Qingdao Haiyang Chemical Factory) and Sephadex LH-20 (Pharmacia Co.) columns. 
TLC was carried out using silica gel GF254 (Qingdao Haiyang Chemical Factory) plates. HPLC was 
performed using an Agilent Chromatography C18 column (5 μm, 9.4 ×  250 mm) with UV detection  
at 254 nm. Mar. Drugs 2010, 8                            
 
 
2750 
3.2. Fungal Material and Taxonomic Identification 
The marine derived fungus Penicillium aurantiogriseum was isolated from marine mud obtained in 
the Bohai Sea, and identified by morphology and sequence analysis of its internal transcribed spacer 
(ITS) region and 5.8S rDNA (GenBank accession number HM587449) using conventional primer pair 
ITS1(5"-TCCGTAGGTGAACCTGCGG-3")  and  ITS4(5"-TCCTCCGCTTATTGATA-TGC-3").  The 
total genomic DNA of marine-derived fungus MF361 was extracted using the EZNA kit (Omega). The 
polymerase chain reaction product is 534 bp. The purified PCR products were sequenced (HuaDa Bio., 
Beijing, China). Multiple alignments with sequences of most closely related fungi and calculations of 
levels of sequence similarity were carried out using CLUSTAL W [29]. The phylogenetic tree was 
constructed using the neighbour-joining method [30], in MEGA 4.0 [31], as shown in Figure 4. The 
topology  of  the  phylogenetic  tree  was  evaluated  by  the  bootstrap  resampling  method  with  1000 
replicates [32]. The fungus has been assigned the accession number MF361 in the culture collection at 
the Institute of Microbiology, Chinese Academy of Sciences, Beijing. 
Figure 4. Neighbour-joining phylogenetic tree of strain MF361. Numbers at nodes indicate 
levels of bootstrap support (%) based on a neighbour-joining analysis of 1000 resampled 
datasets; only values >50% are given. NCBI accession numbers are given in parentheses. 
Bar, 0.01 nucleotide substitutions per site. 
 
3.3. Large Scale Fermentation 
The culture medium  of the strain  consisted of  30 g soybean powder and 120 g rice soaked in 
artificial seawater in a 500 mL erlenmeyer flask. Altogether, 14 flasks were cultured without shaking at 
25 ° C for 20 days before use. 
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3.4. Extraction and Isolation 
The fermentation product was exhaustively extracted with EtOAc-MeOH-AcOH (80:15:5) to yield 
an extract. The crude extract was partitioned between EtOAc and H2O. The EtOAc layer (5.3 g) was 
applied to a column of silica gel using a stepped gradient solvent system of 0 to 100% MeOH/CH2Cl2 
to afford 13 fractions. Fraction B (350 mg) was subjected to a Sephadex LH-20 column, eluted with 
petroleum ether-CH2Cl2-MeOH (5:5:1), to give five subfractions. Compounds 3 (8 mg, 0.15% yield) 
and  4  (12  mg,  0.23%  yield)  were  obtained  by  separation  of  the  subfraction  B1  (62  mg)  on  a  
reversed-phase  HPLC  (Agilent  Zorbax  SB-C18  column,  5  μm,  9.4  ×   250  mm)  eluting  with  80% 
CH3OH in water. While subfraction B3 (91 mg) was further purified on a RP-HPLC eluted with 65% 
MeOH in water to afford compounds 2 (17 mg, 0.32% yield), and a mixture of 5 and 6 (15 mg, 0.28% 
yield). Fraction D was also chromatographed on a Sephadex LH-20 column and eluted with the same 
solvent system as stated above, to afford five subfractions. Subfraction D1 (20 mg) was subjected to 
successive reversed-phase HPLC eluted with 50% acetonitrile in water, and further purified using 40% 
CH3OH in water to afford compound 1 (4 mg, 0.08% yield).  
Verrucosidinol (1): yellow oil, stable in MeOH; []
20
D −10.0°  (c = 0.10, MeOH); UV (MeOH) λmax 
(log ε) 231 (3.91), 288 (3.46) nm; IR vmax 2977, 2916, 2850, 1714, 1558, 1452, 1378, 1089, 1045,  
1018 cm
-1; 
1H and 
13C NMR data, see Table 1; ESIMS m/z [M + Na]
+ 457; HRESIMS m/z 457.2195  
[M + Na]
+ (calcd for C24H34O7, 457.2197 ). 
Verrucosidinol acetate (2): yellow oil, stable in MeOH; []
20
D −34.0°  (c = 0.10, MeOH ); UV (MeOH) 
λmax (log ε) 234 (3.84), 291 (3.45) nm; IR vmax 2973, 2935, 2877, 1745, 1667, 1597, 1452, 1372, 1230, 
1138, 1087, 1043 cm
-1; 
1H and 
13C NMR data, see Table 1; ESIMS m/z [M + Na]
+ 499; HRESIMS  
m/z 499.2300 [M + Na]
+ (calcd for C26H36O8, 499.2302 ). 
3.5. Antimicrobial Assay 
Fresh  Mueller-Hinton  broth  medium  (40  μL)  was  added  to  each  well  of  a  sterilized  96-well 
microtiter plate. To the test wells, 2 μL of the samples to be tested was added followed by 40 μL of the 
test  strain  solutions.  The plate was incubated at 37 ° C overnight. Anti-MRSA and PA activity of 
samples was checked by measuring and comparing the optical diversities of the blank control and test 
wells. All experiments were carried out in triplicate. 
3.6. Antifungal and Synergistic Antifungal Assay 
Candida  albicans  SC5314  was  used  as  a  test  strain  for  antifungal  and  synergistic  antifungal 
bioassay  [33].  All experiments were carried out in flat bottom, 96-well microtiter plates (Greiner, 
Germany), using a broth microdilution protocol modified from the Clinical and Laboratory Standards 
Institute M-27A methods [34].  Overnight cultures  were picked to  prepare the strain  solution  with 
medium RPMI 1640 at the concentration of 1  10
4 cfu/mL. To the test wells in 96 well plates, 2 μL of 
the samples to be tested was added followed by an additional 80 μL of the strain solution. The test 
plates were incubated at 35 ° C for 16 hours. The antifungal positive control was ketoconazole and 
antifungal  MICs  were  determined  by  measuring  and  comparing  the  optical  densities  of  the  blank 
control and test wells. For the synergistic antifungal assay, a quarter of the normal antifungal MIC of Mar. Drugs 2010, 8                            
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ketoconazole was supplemented into the strain solution, and the other procedures were the same as the 
antifungal assay. All experiments were carried out in triplicate. 
4. Conclusions 
Since the initial discovery of penicillin, many new bioactive compounds have been identified from 
the genus Penicillium [12,16,17]. As drug discovery expands into previously underexplored territories, 
such  as  the  marine  environment,  more  new  compounds  will  be  obtained,  for  example,  the  three 
quinazoline alkaloids (aurantiomides A–C), isolated from sponge-derived P. aurantiogriseum [16]. 
The secondary metabolites verrucosidinol (1) and verrucosidinol acetate (2) reported in this study are 
new members of the pyrone-type polyketides. Although they did not show significant bioactivity in 
three  of  the  antimicrobial  assays,  in  consideration  of  their  structural  similarity  to  the  mycotoxin 
verrucosidin, they could potentially have other unexplored bioactivities. 
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